ITRACONAZOLE

Itraconazole is a synthetic triazole antifungal agent belonging to the class of azole derivatives. 
It is widely used in the treatment of systemic and superficial fungal infections. 
Its introduction revolutionized antifungal therapy by offering broad-spectrum activity and relatively favorable pharmacokinetics compared to older antifungals such as ketoconazole.

Developed in the early 1980s by Janssen Pharmaceutica, itraconazole remains an essential antifungal drug with diverse clinical and industrial significance. 
It is structurally characterized by the presence of a triazole moiety, which is essential for its interaction with fungal cytochrome P450 enzymes.

CAS Number: 84625-61-6
Synonyms:,Oriconazole,R 51211,Sporanox (trade name),Itraconazolum (Latin)
Itraconazol (various languages spelling)

Discovered during the expansion of azole antifungals following the success of clotrimazole and ketoconazole.
First approved in Europe in 1988 and later by the FDA in 1992.
Marketed under the trade name Sporanox.
Considered a major step forward in antifungal therapy due to its improved safety profile and broader antifungal coverage compared to ketoconazole.

Chemical Properties
Molecular Formula: C35H38Cl2N8O4
Molecular Weight: 705.64 g/mol
Appearance: White to slightly yellow powder
Melting Point: ~166–170 °C
Solubility: Practically insoluble in water; soluble in methanol, ethanol, chloroform
LogP: ~6.2 (high lipophilicity)
Stability: Stable under acidic conditions; less stable in alkaline conditions
Molecular Structure:
Itraconazole consists of a triazole ring attached to a dioxolane ring system, chlorinated aromatic rings, and a lipophilic side chain. 
This structure is responsible for its high affinity for fungal enzymes and poor water solubility.

Mechanism of Action
Itraconazole inhibits the fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase, which is essential for the biosynthesis of ergosterol. 
Ergosterol is a critical component of fungal cell membranes. Its depletion leads to:
Impaired membrane fluidity
Accumulation of toxic sterol intermediates
Disruption of fungal growth and replication
Itraconazole has fungistatic effects, but can be fungicidal at higher concentrations.

Pharmacokinetics
Absorption
Oral absorption depends on gastric acidity.
The capsule form requires acidic environment for optimal dissolution.
The oral solution has better bioavailability (~55%).

Distribution
Highly lipophilic, widely distributed in tissues, including skin, nails, lungs, and liver.
Plasma protein binding >99%.

Metabolism
Extensively metabolized by the CYP3A4 enzyme system in the liver.
Major metabolite: hydroxy-itraconazole, which has antifungal activity.

Excretion
Eliminated via bile and feces (>50%).
Renal excretion is minimal (<1%).

Pharmacodynamics
Itraconazole has broad antifungal activity against
Candida species
Aspergillus species
Histoplasma capsulatum
Blastomyces dermatitidis
Cryptococcus neoformans
Dermatophytes (Trichophyton, Microsporum, Epidermophyton)

Resistance mechanisms include:
Efflux pump overexpression
Alterations in target enzyme (lanosterol 14α-demethylase)
Reduced intracellular drug accumulation

Formulation and Dosage Forms
Oral capsules (100 mg)
Oral solution (10 mg/mL, cyclodextrin-based for better solubility)
Intravenous formulation (rarely used due to toxicity of solubilizing agents)
Topical formulations (research ongoing, not widely available)

Synthesis and Industrial Production
Itraconazole is synthesized through a multi-step organic synthesis involving:
Preparation of triazole intermediates.
Introduction of chlorinated aromatic groups.
Coupling with a dioxolane ring system.
Final purification and crystallization.
Industrial production emphasizes enantiomeric purity, as stereochemistry is crucial for antifungal activity.

Analytical Methods for Detection
HPLC (High-Performance Liquid Chromatography) – gold standard for plasma monitoring.
LC-MS/MS (Liquid Chromatography–Mass Spectrometry) – highly sensitive.
Spectrophotometry – for pharmaceutical quality control.
Microbiological assays – for potency testing.

Clinical Applications
Itraconazole is indicated for:
Systemic mycoses: Histoplasmosis, Blastomycosis, Sporotrichosis
Onychomycosis: Fungal nail infections
Dermatophytosis: Skin and scalp fungal infections
Prophylaxis in immunocompromised patients (e.g., transplant recipients)
Aspergillosis (chronic and allergic forms)